Tissue recombination and misexpression experiments revealed that endothelial cells are indispensable for ontogeny of the endocrine pancreas ([@B1]). Mice devoid of *Kdr*, the vascular endothelial growth factor (VEGF) receptor type 2, lack endothelial cells and show impaired expression of *Ptf1a*, a functional marker of pancreas progenitor cells, and absence of insulin and glucagon gene expression ([@B2]). Moreover, vascular density near the branching pancreatic epithelium appears crucial for pancreatic cell type specification during development ([@B3]--[@B5]). During development, endothelial cell signaling induces VEGF-A production by β-cells, thereby further increasing islet blood vessel density and permeability ([@B6]--[@B9]). In addition, islet blood vessels provide adult β-cells with a basement membrane that is essential for β-cell proliferation as well as glucose responsiveness of insulin production and secretion ([@B8],[@B10]).

*Pdx1Cre/Vegf^fl/fl^* mice show decreased β-cell mass with a reduced density of insulin granules and impaired insulin gene expression and secretion, resulting in impaired glycemic control ([@B8],[@B11],[@B12]). *RIPCre/Vegf^fl/fl^* mice possess normal β-cell mass but show a retarded glucose clearance and decreased glucose-induced insulin release ([@B7],[@B9]), while insulin secretion from perifused transgenic islets was accelerated compared with wild-type islets ([@B9]). The above models unfortunately lack temporal control and can therefore not distinguish between the effects of VEGF signaling on β-cell mass and function in adult pancreas from those provoked in the developing pancreas. The current study describes a novel, conditional transgenic model to induce islet vessel regression to investigate the genuine role of the islet vasculature of adult mice with regard to β-cell mass and function.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Rat insulin promoter (RIP)-rtTA ([@B13],[@B14]) and TetO*-sFLT1* ([@B4],[@B15]) mice (both on a mixed background, mainly ICR \[CD1\]) were 8--12 weeks old. Experiments were in accordance with the guidelines of our institutional Ethical Committee for Animal Experiments and with the national guidelines and regulations. Genotyping was performed using the following primers: RIPrtTA: 5′-TAGATGTGCTTTACTAAGTCATCGCG-3′ and 5′-GAGATCGAGCAGGCCCTCGATGGTAG-3′; TET-sFLT1: 5′-CGACTCACTATAGGGAGACCC-3′ and 5′-TGGCCTGCTTGCATGATGTG-CTGG-3′. Doxycline (DOX) was administered through the food (625 mg/kg; Harlan Laboratories, Boxmeer, the Netherlands). Tail vein blood glucose level and body weight were evaluated between 10:00 and 12:00 [a.m.]{.smallcaps}, with or without prior fasting (overnight or 2 h), as indicated. Intraperitoneal glucose tolerance tests were performed by injecting glucose (2 g/kg body wt i.p.) after an overnight fast. Mouse islets were isolated from transgenic mice by intraductal injection of 0.3 mg/mL collagenase type XI (Sigma, St. Louis, MO). Handpicked islets were dissociated with trypsin, and β-cells were sorted on the basis of size and flavin adenine dinucleotide content. 80% of the resulting cell preparation consisted of β-cells, as determined by immunostaining for insulin. Sustained-release insulin implants (LinBit, LinShin, Toronto, Canada) (1 implant per mouse) were implanted subcutaneously under the mid-dorsal skin. Partial pancreatic duct ligation (PDL) and partial (60%) pancreatectomy (PPx) were performed as previously described ([@B16],[@B17]).

RNA and protein analysis. {#s2}
-------------------------

Total RNA was isolated from tissue (TRIzol; Life Technologies, Carlsbad, CA), from islets (RNeasy; Qiagen, Venlo, the Netherlands), or from cells (PicoPure; Life Technologies). Only RNA with RNA integrity number ≥7 was retained for analysis. cDNA synthesis and RT--quantitative PCR was done as described ([@B18]). Quantitative PCR was performed using mouse-specific Assays on Demand (Applied Biosystems, Life Technologies) (see [Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)) with TaqMan Universal PCR master mix on an ABI Prism 7700 Sequence Detector, and data were analyzed using the Sequence Detection Systems Software, version 1.9.1 (all Applied Biosystems). For avoidance of interference from contaminating genomic DNA, primer sets were designed to span at least one intron. Expression levels were normalized to the expression level of the housekeeping gene *Ppia*.

For primary antibodies used, see [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1). Secondary antibodies were cyanine-labeled (Jackson ImmunoResearch, Newmarket, U.K.). Nuclei were labeled with Hoechst 33342. GLUT2 was detected using an ImmPRESS Polymer Detection kit (Vector Laboratories, Burlingame, CA). Sections were imaged using a Zeiss Axioplan 2 microscope. Scale bars are 100 µm. The measurement of β-cell mass and β-cell mass distribution according to endocrine cluster size was performed as previously described ([@B19]). For quantitation of β-cell proliferation, percentages of Ki67-positive β-cells were measured as mean ± SEM. For all conditions, at least 1,500 β-cells were counted. Insulin content of pancreas was determined with a mouse insulin RIA kit (Linco Research, St. Charles, MO). Insulin release by islets (20 freshly isolated islets per condition) was measured after preincubation in Ham F10 medium without glucose for 2 h at 37°C and 5% CO~2~ and incubation for 2 h in Ham F10 medium containing 2 mmol/L Ca^2+^ and either 2 mmol/L (G2), 10 mmol/L (G10), or 20 mmol/L (G20) glucose. Insulin content of medium and cells was measured with a mouse insulin RIA kit (Linco Research). β-Cell area was determined by morphometric analysis on E-cadherin/insulin-stained slides using ImageJ. Relative amount of α-cells was evaluated by expressing the glucagon-positive area as percentage of total islet area, calculated as sum of insulin- and glucagon-positive areas.

Measurement of vascularization and hypoxia. {#s3}
-------------------------------------------

Functional vessels were labeled by intravenous injection of biotinylated tomato lectin (Lycopersicon esculentum; Vector Laboratories) ([@B20]). Five minutes after injection, intravenous blood cells were flushed from the circulation of anesthetized mice by systemic perfusion with PBS, followed by overnight fixation of the samples at 4°C with 10% (vol/vol) neutral-buffered formalin prior to paraffin embedding and sectioning. Tomato lectin was visualized with Alexa Fluor 555--labeled streptavidin (Life Technologies). Intraislet vessel density was calculated by morphometric analysis using IPLab Pathway 4.0 for PC (BD) and represents the proportion of the amount of tomato lectin--positive vessels per islet area (number of vessels × 1,000 per number of insulin-positive pixels). For detection of hypoxia, the oxygenation marker pimonidazole (60 mg/kg body wt i.p.; HPI, Burlington, MA) was injected. One hour after injection, the animals were anesthetized, followed by systemic perfusion during 10 min with 10% (vol/vol) neutral-buffered formalin. Organs were embedded in paraffin without postfixation, sectioned, and reacted with a mouse anti--hypoxyprobe-1 antibody (HPI) after heat-mediated antigen retrieval using 0.1 mol/L glycine, pH 9.0. Chromogenic detection was done with an EnVision+ kit (Dako) according to manufacturer's instructions.

Pancreas perfusion. {#s4}
-------------------

Perfusion of mouse pancreases was performed as previously described ([@B21]). Briefly, mice were fasted overnight. Pancreata were perfused at 1 mL/min during 10 min with Krebs-Ringer bicarbonate (KRB) HEPES buffer containing 2.8 mmol/L glucose, followed by 15 min perfusion with KRB buffer containing 16.7 mmol/L glucose and ending with KRB buffer containing 2.8 mmol/L glucose. Insulin in the perfusate was measured by the homogeneous time-resolved fluorescence--based assay (CIS Bio International, Gif sur Yvette, France).

Glucose oxidation and utilization. {#s5}
----------------------------------

For measurements of glucose oxidation and utilization, batches of 15 islets were incubated in KRB HEPES/0.25% (wt/vol) BSA containing 1 μCi [d]{.smallcaps}-\[U-^14^C\]glucose/5 mL (300 mCi/mmol) and 1 μCi [d]{.smallcaps}-\[5-^3^H\]glucose/mL (13.5 Ci/mmol) at 2.5, 10, and 20 mmol/L glucose for 2 h. Glucose oxidation was measured by the generation of KOH-trapped ^14^CO~2~, and glucose utilization was determined by measuring the amount of ^3^H~2~O generated as previously described ([@B22]).

Electron microscopy. {#s6}
--------------------

Samples were fixed in 2.5% (vol/vol) glutaraldehyde in 0.1 mol/L sodium cacodylate buffer, pH 7.4, postfixed in 1% (wt/vol) osmium tetroxide, stained with 2% (wt/vol) uranyl acetate, and embedded in Spurr resin, and ultra-thin plastic sections were examined with a ZEISS EM 9S2 electron microscope.

Data analysis. {#s7}
--------------

Values are depicted as mean ± SEM from at least three independent experiments and considered significant when *P* ≤ 0.05. Data were statistically analyzed by (un)paired Student *t* test, one-way ANOVA with Bonferroni posttest, or one-sample *t* test as indicated (GraphPad Prism, version 5.0b \[<http://www.graphpad.com>\]).

RESULTS {#s8}
=======

*sFLT1* overexpression in β-cells severely reduces the islet vascular network. {#s9}
------------------------------------------------------------------------------

Double transgenic (dTG) mice were generated by crossing driver mice that express reverse tetracycline *trans*-activator (rtTA) under the control of the RIP with responder mice that express human *sFLT1* when rtTA binds to the operator sequence (TetO) in the presence of tetracycline or DOX ([Fig. 1*A*](#F1){ref-type="fig"}). β-Cells from these double transgenic mice thus conditionally produce human soluble Flt1 (sFlt1), a splice variant of the VEGF receptor 1 (*Flt1*) that binds extracellular VEGF or PlGF and thereby antagonizes their signaling ([@B15]). Since β-cells attract blood vessels by releasing VEGF ([@B11]), we hypothesized that the high local levels of sFLT1, produced and secreted by β-cells, would interfere with the cross-talk between β- and endothelial cells and might thereby reduce islet vascularization and, presumably, oxygenation. To test the specificity and efficacy of *sFLT1* expression/production, 8- to 12-week-old RIP^rtTA^TetO*^sFLT1^* dTG or TetO*^sFLT1^* single transgenic (sTG) mice were fed DOX-containing chow during 2 weeks (DOX^2W^). Under these conditions, the transcript encoding *sFLT1* was significantly induced ([Fig. 1*B*](#F1){ref-type="fig"}), resulting in production of sFlt1 protein by the majority of β-cells ([Fig. 1*B* and *C*](#F1){ref-type="fig"}) and a decrease of 68% compared with dTG^−^ and of 71% compared with sTG^+^ of functional intraislet vessels compared with sTG-DOX^2W^ and dTG+DOX^2W^ control mice ([Fig. 2*A*](#F2){ref-type="fig"}). In parallel, laminin and collagen IV, two major components of the vascular basement membrane in islets ([@B8],[@B10]), were nearly absent after 2 weeks of DOX treatment, while the peripheral islet basement membrane remained intact ([Fig. 2*B*](#F2){ref-type="fig"} and [Supplementary Fig. 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)). Given the near-identical phenotype of sTG+DOX^2W^ and dTG-DOX^2W^ mice, only dTG-DOX^2W^ mice were used as control from then on.

![Efficient overexpression of *sFLT1* in β-cells of dTG+DOX^2W^ mice. *A*: Schematic illustration of the RIPrtTA × TetO-*sFLT1* model. *B*: DOX induces efficient *sFLT1* overexpression in β-cells of dTG mice. *Left panel*: *sFLT1* transcript level is increased in islets, isolated from dTG+DOX (dTG^+^) mice (*n* = 3; result expressed relative to expression level in dTG-DOX mice \[dTG^−^\]). *Right panel*: Percentage of β-cells that produce sFlt1 is increased in dTG+DOX mice (*n* = 3--4). *C*: sFlt1 (red) is specifically overproduced in β-cells (insulin \[green\]) of dTG+DOX mice. All analyses were done after 2 weeks ± DOX. Data were statistically analyzed by one-way ANOVA with Bonferroni posttest. \**P* ≤ 0.05, \*\*\**P* ≤ 0.001. ND, nondetectable.](4165fig1){#F1}

![Overexpression of *sFLT1* in β-cells leads to islet hypovascularization, altered islet structure, and islet hypoxia. *A*, *upper panel*: Pancreas sections stained for the functional vessel marker lectin (red) and insulin (green). *Lower panel*: Intraislet vessel density is reduced in dTG+DOX mice (*n* = 9). Intraislet vessel density represents the proportion of the amount of tomato lectin--positive vessels per islet area (number of vessels × 1,000 per number of insulin-positive pixels). *B*: Reduction of vascular basement membrane (laminin \[red\]) in dTG+DOX mice. Functional vessels are stained with lectin (green) and β-cells with insulin (blue). *C*: Thickening of the endothelial lining and absence of fenestrae (indicated with asterisks) in dTG+DOX mice. Note the increased prevalence of plasma membrane invaginations (caveolae, arrowhead) and the predominance of α-cells surrounding the depicted blood vessel in the dTG+DOX condition (*upper right panel*). A, α-cell; B, β-cell. *D*: Hypovascularization induces islet hypoxia in dTG+DOX mice. Pancreas sections stained with antibody against hypoxyprobe (pimonidazole) (brown). Liver from the same animals served as positive control. All analyses were performed after 2 weeks ± DOX. Data were statistically analyzed by one-way ANOVA with Bonferroni posttest. \*\*\**P* ≤ 0.001.](4165fig2){#F2}

Compared with control mice, very few fenestrae were detected in the few remaining intraislet endothelial cells in dTG+DOX^2W^ mice, while they contained an increased number of plasma membrane invaginations (caveolae) ([Fig. 2*C*](#F2){ref-type="fig"}). Moreover, these endothelial cells were predominantly surrounded by α- rather than by β-cells ([Fig. 2*C*](#F2){ref-type="fig"}).

Intraislet hypoxia was evaluated by intravenous injection of pimonidazole that precipitates at oxygen levels of ≤8 mmHg ([@B23]). Islets from dTG+DOX^2W^ mice stained positive for pimonidazole with medium/large islets (\>100 µm diameter) displaying more pimonidazole^+^ cells than small islets (\<100 µm diameter) (29.0 ± 2.4% in \<100 µm vs. 46.4 ± 7.0% in \>100 µm) (*n* = 4). The intensity of pimonidazole staining was more heterogeneous in medium/large islets and inversely related to the distance toward the most proximate blood vessel ([Fig. 2*D*](#F2){ref-type="fig"} and [Supplementary Fig. 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)). Whether pimonidazole precipitation associated with functionally important and metabolically relevant hypoxia was evaluated by analysis of transcripts encoding *Hif1a/Vegfa* and glycolytic enzymes in islets isolated from dTG+DOX^2W^ mice. Although HIF1a protein could be observed in the nuclei of islet cells, neither *Hif1a* nor *Vegfa* mRNA levels were significantly altered 2 weeks after sFlt1-mediated vessel ablation. Expression of *Flt1* (*VEGFR1*), *Kdr* (*VEGFR2*), and *Flt4* (*VEGFR3*) was significantly reduced in DOX^2W^-treated animals, coinciding with the observed vessel regression ([Supplementary Fig. 3*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)). Immunostaining showed an increased amount of nuclear HIF1-α, a similar level of VEGF, and a severe decrease in KDR and FLT4 in dTG+DOX^2W^ mice ([Supplementary Fig. 3*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)). Transcript levels of glyceraldehyde 3-phosphate dehydrogenase (*Gapdh*), phosphoglycerate kinase 1 (*Pgk1*), pyruvate dehydrogenase kinase 1 (*Pdk1*), and phosphofructokinase 1 (*Pfk1*) only marginally increased (% increase vs. dTG-DOX: *Gapdh*, 37.3 ± 4.1%; *Pgk1*, 30.0 ± 4.7%; *Pdk1*, 26.0 ± 14.0%; and *Pfk1*, 8.9 ± 4.3% \[all *n* = 3\]) In line with the absence of increased *Hif1a* and *Vegfa* gene expression, no significant differences in expression of the HIF1a downstream targets lactate dehydrogenase A (*Ldha*) or DNA-damage-inducible transcript 4 (*Ddit4*) were observed ([Supplementary Fig. 4](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)). Taken together, time-controlled and β-cell--specific overexpression of *sFLT1* results in severe islet hypovascularization but only mild hypoxia and subtle changes in the expression of glycolytic and hypoxia-regulated genes.

Hypovascularization and hypoxia impair fasting glucose and blunt glucose-stimulated insulin release but do not overtly influence isolated β-cell function. {#s10}
----------------------------------------------------------------------------------------------------------------------------------------------------------

For examination of the effect of islet hypovascularization on glucose homeostasis, blood glucose was measured after overnight and/or 2-h fasting in dTG ± DOX mice after 2 (dTG ± DOX^2W^) or 25 (dTG ± DOX^25W^) weeks of DOX treatment. While, at both time points, body weight did not differ between both experimental conditions ([Fig. 3*A*](#F3){ref-type="fig"}), blood glucose level was only marginally elevated in dTG+DOX mice after overnight fasting but was more severely increased after 2 h of fasting (overnight fasting, 79.8 ± 7.3 mg/dL \[*n* = 15\] in dTG-DOX^2W^ vs. 100.1 ± 5.9 mg/dL in dTG+DOX^2W^ \[*n* = 15\] (*P* ≤ 0.05); 2-h fasting, 125.8 ± 5.1 mg/dL (*n* = 8) in dTG-DOX^2W^ vs. 179.8 ± 9.0 mg/dL in dTG+DOX^2W^ (*n* = 8) (*P* ≤ 0.005); and 2 h-fasting, 140.8 ± 6.7 mg/dL (*n* = 4) in dTG-DOX^25W^ vs. 190.0 ± 12.9 mg/dL in dTG+DOX^25W^ (*n* = 4) (*P* ≤ 0.05) ([Fig. 3*B*and*C*](#F3){ref-type="fig"} and [Supplementary Fig. 5](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)). Similarly, rapid glucose clearance was impaired upon intraperitoneal glucose administration in dTG+DOX^2W^ mice (glycemia after 2-h intraperitoneal glucose tolerance test: 112.3 ± 6.6 mg/dL \[dTG-DOX^2W^\] vs. 181.0 ± 18.6 mg/dL \[dTG+DOX^2W^\]) (*P* ≤ 0.05; *n* = 11) ([Fig. 3*D*](#F3){ref-type="fig"}). For determination of whether this glucose intolerance was caused by defective glucose-stimulated insulin release in vivo, pancreases were perfused with 20 mmol/L glucose, showing a dramatic decrease in first-phase insulin secretory response from hypovascular, hypoxic islets ([Fig. 3*E*](#F3){ref-type="fig"}).

![Islet hypovascularization and hypoxia results in impaired fasting glucose and blunted glucose-stimulated insulin secretion with subsequent impaired glucose tolerance. *A*: Body weight is unchanged in dTG+DOX mice (*n* = 5). *B* and *C*: Overnight (*n* = 15) (*B*) and 2-h (*C*) fasting glycemia (*n* = 8) is increased in dTG+DOX mice. *D*: Impaired glucose tolerance in dTG+DOX mice (*n* = 11). *E*: In vivo pancreas perfusion (*n* = 4). Glucose-stimulated insulin release is blunted in dTG+DOX mice. All analyses were done after 2 weeks ± DOX. Data were statistically analyzed by unpaired *t* test. \**P* ≤ 0.05, \*\**P* ≤ 0.01, \*\*\**P* ≤ 0.001. hrs, hours; ON, overnight.](4165fig3){#F3}

The possibility of intrinsic defects in glucose handling by hypovascular and hypoxic β-cells as a cause for the differences in glucose homeostasis was evaluated by analysis of transcripts coding for Glut type 1/2 (*Slc2a1* and *Slc2a2*, respectively) and glucokinase (*Gck*) and by analysis of in vitro glucose utilization and oxidation. Although Glut1 expression increased by 58% and Glut2 and glucokinase expression decreased by 31 and 23%, respectively, in hypovascular islets ([Fig. 4*A*and*B*](#F4){ref-type="fig"}), in vitro glucose utilization and oxidation were similar, with the exception of a significant increase in glucose utilization at 20 mmol/L glucose in islets, isolated from DOX-treated animals ([Fig. 4*C*and *D*](#F4){ref-type="fig"}). Surprisingly, insulin gene expression and total pancreas insulin content remained unaffected (78.80 ± 13.79 pg insulin/mg tissue in dTG-DOX^2W^ vs. 65.87 ± 10.46 pg insulin/mg tissue in dTG+DOX^2W^ (*n* = 5, *P* = 0.48) ([Fig. 4*A*and*E*](#F4){ref-type="fig"}), while glucose-stimulated insulin secretion by hypovascular, hypoxic islets demonstrated a significant increase at 20 mmol/L ([Fig. 4*F*](#F4){ref-type="fig"}).

![Islet hypovascularization and hypoxia do not overtly influence β-cell function. *A*: Transcript level is increased for *Slc2a1* (Glut1) (*n* = 3), decreased for *Slc2a2* (Glut2) (*n* = 4) and glucokinase (*Gck*) (*n* = 4), and unchanged for insulin (Ins1/2) (*n* = 3) in islets, isolated from dTG+DOX mice. Results are expressed relative to their expression level in dTG-DOX islets, which is set at 1. *B*: Pancreas sections stained for GLUT2, illustrating decreased membrane expression of GLUT2 in dTG+DOX mice. *C* and *D*: In vitro glucose utilization (*n* = 5) (*C*) and oxidation (*n* = 5) (*D*) are unchanged in islets, isolated from dTG+DOX mice, except for an increase in glucose utilization at 20 mmol/L glucose. *E*: Pancreas insulin content (*n* = 5) is unchanged in dTG+DOX mice. *F*: Insulin release from β-cells, isolated from dTG+DOX mice, is increased at 20 mmol/L glucose (results are expressed as % of total insulin content) (*n* = 4). All analyses were done after 2 weeks ± DOX. Data were statistically analyzed by one-sample *t* test (*A*) or by (un)paired *t* test (*B*--*F*). G2.5, 2.5 mmol/L glucose; G10, 10 mmol/L glucose; G20, 20 mmol/L glucose. \**P* ≤ 0.05.](4165fig4){#F4}

Taken together, these data indicate that islet hypovascularization and hypoxia correlate with increased fasting glucose, blunted glucose-stimulated insulin release, and impaired glucose tolerance in vivo but do not irreversibly influence β-cell function in isolated β-cells.

Hypovascularization and hypoxia do not influence β-cell proliferation or mass. {#s11}
------------------------------------------------------------------------------

Since both VEGF signaling and vascular basement membrane proteins have been claimed to be instrumental for proper β-cell formation and postnatal proliferation by nonconditional models of VEGF ablation ([@B1],[@B8]), we evaluated the effect of spatiotemporal ablation of the endothelium and associated basement membrane on β-cell proliferation and mass after 2 and 25 weeks of *sFLT1* overexpression. Interestingly, β-cell proliferation was independent of *sFLT1* overexpression and of glycemia that was normalized by an insulin-releasing implant (0.5 ± 0.1% Ki67^+^insulin^+^ cells in dTG ± DOX^2W^ \[*n* = 11\], 0.4 ± 0.1% in dTG+DOX^2W+INS\ pellet^ \[*n* = 6\], 0.4 ± 0.1% in dTG-DOX^25W^ \[*n* = 9\], and 0.3 ± 0.1% in dTG+DOX^25W^ \[*n* = 8\] mice) (*P* \> 0.05 for comparison of all conditions) ([Fig. 5*A*](#F5){ref-type="fig"} and [Supplementary Fig. 6](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)). β-Cell proliferation was not increased in small compared with large islets of dTG+DOX^2W\ and\ 25W^ mice ([Supplementary Table 3](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)). In addition, β-cell mass was similar in dTG ± DOX^2W\ and\ 25W^ mice (2.2 ± 0.2 mg in dTG ± DOX^2W^ \[*n* = 4; *P* \> 0.5\], 3.2 ± 0.5 mg in dTG-DOX^25W^, and 3.3 ± 0.5 mg in dTG+DOX^25W^ mice \[*n* = 4; *P* \> 0.5\]) ([Fig. 5*B*](#F5){ref-type="fig"}). For determination of whether islet hypovascularization influenced β-cell area or islet size, β-cell surface was measured and islets were classified on the basis of their size. No differences in surface area per β-cell or in islet size were found between dTG ± DOX^2W^ mice ([Fig. 5*C* and *E*](#F5){ref-type="fig"}). In contrast, β-cell size was smaller in dTG+DOX^25W^ mice. The decreased β-cell size likely contributes to the increased number of small islets (12--100 µm in diameter) in dTG+DOX^25W^ mice ([Fig. 5*D*and*E*](#F5){ref-type="fig"}). While islet cell composition was similar in medium- and larger-sized islets, the number of α-cells increased by 69% in small islets of dTG+DOX^25W^ ([Fig. 5*F*](#F5){ref-type="fig"}). Despite these subtle differences in β-cell area, islet size, and islet composition, these data suggest that the islet endothelium and the associated basement membrane proteins are dispensable for postnatal β-cell proliferation and β-cell mass expansion under normal physiological conditions.

![Islet hypovascularization and hypoxia do not influence maintenance or growth of adult β-cells. *A*--*E*: β-Cell proliferation after 2 weeks (*n* = 11) and 25 weeks (*n* = 4) (*A*), β-cell mass after 2 weeks (*n* = 4) and 25 weeks (*n* = 4) (*B*), islet size after 2 weeks (*n* = 4) (*C*) and 25 weeks (*n* = 4) (*D*), and β-cell area after 2 weeks (*n* = 10) and 25 weeks (*n* = 3) (*E*) are unchanged in dTG+DOX mice except for an increase in small islets (12--100 µm diameter) (*D*) and a decrease in β-cell area in dTG+DOX mice after 25 weeks (*E*). *F*: α-Cell prevalence, measured as ratio of glucagon-positive area over (glucagon + insulin)-positive area, is increased in small islets of dTG mice after 25 weeks of DOX treatment (*n* = 4). Data were statistically analyzed by unpaired *t* test. \**P* ≤ 0.05.](4165fig5){#F5}

Hypovascularization and hypoxia do not influence injury-induced increase of β-cell proliferation. {#s12}
-------------------------------------------------------------------------------------------------

Since islet hypovascularization and hypoxia exerted only minor effects on β-cell function and mass under normal physiological conditions, we evaluated whether the islet endothelium was necessary for injury-induced β-cell proliferation ([@B16],[@B17]). DOX was administered for 7 or 14 days, respectively, immediately after injury by 60% PPx or partial PDL. Two weeks after PDL, the number of sFlt1-producing β-cells was significantly increased in DOX^2W^ animals ([Supplementary Fig. 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)), associated with hypovascularization and regression of the vascular basement membrane ([Supplementary Fig. 8](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-1827/-/DC1)). Despite these structural changes, β-cell proliferation was similar in PDL pancreas of dTG ± DOX^2W^ mice (1.8 ± 0.3% in dTG^−^ vs. 2.2 ± 0.3% in dTG^+^ \[*n* = 6\]) ([Fig. 6*A*and*C*](#F6){ref-type="fig"}). Similarly, 1 week after PPx, no differences in β-cell proliferation were observed between dTG ± DOX^1W^ mice (4.5 ± 0.6% in dTG^−^ vs. 5.3 ± 0.2% in dTG^+^ \[*n* = 4\]) ([Fig. 6*B*and *C*](#F6){ref-type="fig"}). These data therefore do not imply a role for the islet endothelium or of its basement membrane in PDL- or PPx-mediated β-cell generation.

![Islet hypovascularization and hypoxia do not influence injury-induced β-cell proliferation. *A* and *B*: Pancreas sections from partial duct-ligated (*A*) or partial pancreatectomized (*B*) dTG mice stained for Ki67 (red) and insulin (green). *C*: β-Cell proliferation is similar in duct-ligated (*n* = 6) and partial pancreatectomized (*n* = 4) dTG+DOX compared with duct-ligated or partial pancreatectomized dTG-DOX mice. All analyses were done 2 weeks after PDL or PPx ± DOX. Data were statistically analyzed by unpaired *t* test.](4165fig6){#F6}

DISCUSSION {#s13}
==========

Islets of Langerhans are highly vascularized mini-organs ([@B1],[@B8],[@B11]) in which β-cells are arranged in a rosette-like pattern around blood vessels ([@B24],[@B25]). This structural organization is suggestive for the importance of endothelial-endocrine cross-talk. Indeed, endothelial cells are indispensible for proper endocrine development ([@B1],[@B2]), while β-cells attract endothelial cells by secreting and releasing VEGFA ([@B7]--[@B9],[@B11]). The role of VEGF and the islet endothelium has been studied in mice with *Vegf* knockout in PDX1^+^ ([@B6],[@B8]) or insulin^+^ cells ([@B7],[@B9]). Depletion of VEGF already during the ontogeny of these mice excludes the study of postnatal effects of VEGF on β-cell function and mass. To circumvent this caveat and determine the genuine role of endothelial--β-cell cross-talk on adult β-cell function and mass, we generated a β-cell--specific, DOX-inducible genetic system in which a secreted VEGF-trap (sFlt1) specifically interfered with VEGF signaling near β-cells of 8- to 12-week-old mice.

Impaired VEGF signaling in adult islets significantly decreased islet vessel density within 14 days. While the peri-islet basement membrane remained intact, intraislet vessel regression was associated with a loss of the vascular basement membrane. The few remaining vessels mainly associated with α-cells and displayed, in line with the observations from others ([@B11]), very few fenestrae and a high number of plasma membrane invaginations (caveolae). This observation indicates that islet blood vessels require continuous VEGF signaling for their maintenance and proper fenestration.

Islet hypovascularization causes intraislet hypoxia and compensatory metabolic adapatations. As reported by others ([@B26]--[@B28]), we observed that intraislet hypoxia resulted in increased gene expression of glycolytic enzymes, be it to a limited extent. While hypoxia and the resulting signaling have been claimed to be important for glucose sensing and metabolic control by β-cells ([@B27]--[@B33]), blood glucose level was only moderately elevated in dTG+DOX mice, even after 25 weeks of *sFLT1* overexpression. Despite subtle differences in expression levels of Glut1/2 and glucokinase, isolated hypovascular islets displayed normal glucose utilization and oxidation profiles, illustrating a remarkable capacity of β-cells to cope with intraislet hypoxia. Nevertheless, our data still attribute an important role to the islet endothelium, since mice with hypovascular islets display a significant decrease of glucose responsiveness of insulin secretion in vivo, contributing to glucose intolerance upon intraperitoneal glucose load. The observed lack of a clear first-phase insulin secretory response of hypovascular islets is likely due to impaired β-cell insulin synthesis and secretion in vivo or to the decreased amount of intraislet vessels, mainly associated with α-cells, leading to a delay in time before glucose can reach the β-cells and for insulin to diffuse to the nearest vessel(s). Moreover, hypoxia-mediated stabilization of HIF1a could additionally explain the observed decrease in glucose-stimulated insulin secretion in vivo as previously reported ([@B26]). Of note, hypoxia predominantly affects the second phase of glucose-stimulated insulin secretion in rat and canine islets ([@B30],[@B31]); however, this was not observed by us and others, since the second phase of insulin secretion is blunted in mice ([@B34]).

In contrast to prenatal *Vegfa* deletion ([@B7]--[@B9],[@B11],[@B12]), postnatal interference with VEGF-A signaling and subsequent vascular (basement membrane) regression did not influence insulin gene expression, pancreas insulin content, or basal β-cell proliferation rate. As a consequence, the β-cell mass did not differ from control animals. Interestingly, after 25 weeks of *sFLT1* expression, the β-cell size was subtly reduced and an increased amount of small islets with increased α--to--β-cell ratio could be observed. Although further examination is needed, this finding could be attributed to fission of large islets or neoformation of islets ([@B35]). While recently it was reported that (*Pdx1* promoter driven) blood vessel ablation promoted pancreatic branching, differentiation, and growth during embryogenesis ([@B4]), only minor changes in β-cell size and islet composition were observed after selective ablation of intraislet blood vessels in the adult pancreas in our study. Whether manipulation of the vasculature throughout the entire adult pancreas or more specifically near the ductal epithelium would alter pancreas size or the activation of facultative (endocrine) progenitors remains to be determined. Finally, while signals from activated endothelial cells have been demonstrated to be instrumental for compensatory β-cell proliferation and β-cell mass expansion during pregnancy ([@B36]), our data reveal that blood vessels are dispensable for normal, age-dependent augmentation of the β-cell mass and for injury-induced β-cell generation.

Conditional intraislet blood vessel ablation thus enabled clarification of the role of intraislet endothelial cells with regard to adult β-cell function, mass, and proliferation, restricting their importance to proper rapid and adequate glucose-stimulated insulin secretion. The current report could have major implications for design of islet transplantation protocols. Indeed, efforts are currently undertaken to promote early graft revascularization. Our data, however, indicate that β-cells can survive, function, and even proliferate in a hypovascular and hypoxic state, thereby suggesting that *1*) insufficient vascularization upon transplantation is likely not the predominant cause of early graft loss and *2*) approaches that uniquely promote graft revascularization will likely not result in a major benefit for glycometabolic outcome of islet transplantation.
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